Benign Prostatic Hyperplasia Therapeutics Market by Therapeutic Class (Alpha Blocker, 5- Alpha Reductase Inhibitor, Phosphodiesterase-5 Inhibitor, and Others), and Therapy (Mono Drug Therapy and Combination Drug Therapy) – Global Opportunity Analysis and Industry Forecast 2025
The report on “Benign Prostatic Hyperplasia Therapeutics Market” will help Major Players and the new entrants to understand scrutinize the market in detail. This information will encourage the Major Players to decide their business strategy and achieve proposed business aims.
The prostate is a walnut-sized gland that surrounds the urethra in the male reproductive system. The main function of this gland is to secrete a fluid, which mixes with the fluids from other glands and sperm cells from the testicles to generate semen. Benign prostatic hyperplasia (BPH) is a non-malignant increase in the size of the prostate gland. This increase blocks the urine flow from the bladder, which results in increased urination frequency at night, urinary hesitancy, and urinary retention. BPH significantly influences the patient’s quality of life, owing to symptoms, such as urine leakage and nocturia. If untreated for a long duration, it results in more serious health issues, such as bladder damage, bladder stones, kidney damage, and urinary tract infections (UTIs).
Top Companies Covered in this Report:
Abbott Laboratories, Allergan plc, Astellas Pharma, Inc., Boehringer Ingelheim Pharma GmbH & Co. KG, Eli Lilly and Company, GlaxoSmithKline plc, Merck & Co., Inc., Pfizer, Inc., Sanofi, Teva Pharmaceutical Industries Limited
Get sample copy of “Benign Prostatic Hyperplasia Therapeutics Market” at: https://www.premiummarketinsights.com/sample/AMR00013909
The global benign prostatic hyperplasia therapeutics market was valued at $10,688.72 million in 2017, and is projected to reach $20,096.68 million by 2025 at a CAGR of 8.1% from 2018 to 2025. This market is majorly driven by an increase in the male geriatric population because the disease generally occurs in men of age 60 and above. The other factors boosting the market growth include growth in awareness related to urological disorders and prostate cancer and rise in the number of global benign prostatic hyperplasia patients. However, preferences for minimally-invasive surgeries namely, laparoscopic prostatectomy, transurethral needle ablation (TUNA), and transurethral microwave thermotherapy (TUMT), hinder the growth of the global BPH therapeutics market. Furthermore, presence of a plethora of products in the pipeline and high market potential in untapped emerging economies are anticipated to serve as attractive opportunities during the forecast period.
Key Benefits for Stakeholders:
The report provides an extensive analysis of the current and emerging Benign Prostatic Hyperplasia Therapeutics market trends.
It offers quantitative analysis, which assists to identify the prevailing market opportunities.
Comprehensive analysis of factors that drive and restrict the market growth are provided in the report.
Competitive intelligence of leading players of Benign Prostatic Hyperplasia Therapeutics helps understand the competitive scenario across geographies.
Have any query? Enquire about report at: https://www.premiummarketinsights.com/discount/AMR00013909
Fundamentals of Table of Content:
1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered
1.4 Market Analysis by Type
1.5 Market by Application
1.6 Study Objectives
1.7 Years Considered
2 Global Growth Trends
2.1 Benign Prostatic Hyperplasia Therapeutics Market Size
2.2 Benign Prostatic Hyperplasia Therapeutics Growth Trends by Regions
2.3 Industry Trends
3 Market Share by Key Players
3.1 Benign Prostatic Hyperplasia Therapeutics Market Size by Manufacturers
3.2 Benign Prostatic Hyperplasia Therapeutics Key Players Head office and Area Served
3.3 Key Players Benign Prostatic Hyperplasia Therapeutics Product/Solution/Service
3.4 Date of Enter into Benign Prostatic Hyperplasia Therapeutics Market
3.5 Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Product
4.1 Global Benign Prostatic Hyperplasia Therapeutics Sales by Product
4.2 Global Benign Prostatic Hyperplasia Therapeutics Revenue by Product
4.3 Benign Prostatic Hyperplasia Therapeutics Price by Product
5 Breakdown Data by End User
5.2 Global Benign Prostatic Hyperplasia Therapeutics Breakdown Data by End User
Get Complete Report at: https://www.premiummarketinsights.com/buy/AMR00013909
Email: [email protected]
Premiummarketinsights.com is a one stop shop of market research reports and solutions to various companies across the globe. We help our clients in their decision support system by helping them choose most relevant and cost effective research reports and solutions from various publishers. We provide best in class customer service and our customer support team is always available to help you on your research queries.